SCHEMBL8100707

SCHEMBL8100707

O=CC1=CCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807733 0.71
SCHEMBL8091651 0.70 GLA (0.36)
SCHEMBL263522 0.68
SCHEMBL21309666 0.67 HTR1D (0.37)
SCHEMBL4080982 0.65
SCHEMBL2152167 0.64 MAPK1 (0.33)
SCHEMBL20387096 0.64
SCHEMBL22657722 0.63 PIK3CD (0.39)
SCHEMBL15178398 0.62 CA1 (0.33)
SCHEMBL1446770 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619104-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS Novartis AG (CH) 2025-09-24 EP disclosed
US-12336991-B2 Factor XIIA inhibitors UNIVERSITY OF LEEDS (GB) 2025-06-24 US disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 US disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 US disclosed
WO-2024105553-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS NOVARTIS AG (CH) 2024-05-23 WO disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 WO disclosed
EP-4347596-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) Novartis AG (CH) 2024-04-10 EP disclosed
US-11878973-B2 Bicyclic compounds and their uses NOVARTIS AG (CH) 2024-01-23 US disclosed
CN-117425657-A Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) 诺华股份有限公司 2024-01-19 CN disclosed
US-9029540-B2 Ruthenium catalysts and their use for asymmetric reduction of ketones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-05-12 US disclosed
US-9029540-B2 Ruthenium catalysts and their use for asymmetric reduction of ketones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-05-12 US disclosed
WO-2015002769-A1 NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-08 WO disclosed
WO-2015002769-A1 NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-08 WO disclosed
US-20150005500-A1 NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-01 US disclosed
US-20150005500-A1 NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-01 US disclosed
US-20150005500-A1 NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-01 US disclosed
US-6107254-A USE IN HERBICIDAL COMPOSITIONS AND PLANT-GROWTH REGULATING COMPOSITIONS BASF AKTIENGESELLSCHAFT (DE) 2000-08-22 US disclosed
EP-0964866-A1 5-(DIOXABICYCLOHEPT-6-YL)-CYCLOHEXENONE OXIME ETHERS, THEIR PREPARATION AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1999-12-22 EP disclosed
WO-1998030565-A1 5-(DIOXABICYCLOHEPT-6-YL)-CYCLOHEXENONE OXIME ETHERS, THEIR PREPARATION AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1998-07-16 WO disclosed